Latest Industry Insights

Degenerative disc diseases are debilitating, and treatment options are lacking. Three leaders from Discgenics explain how they are harnessing the restorative potential of cells native to the intervertebral disc to alleviate lower back pain.

Following the recent FDA approval of a procalcitonin assay, we spoke with a representative from Fujirebio Diagnostics, Inc. to learn how measuring this important biomarker will improve the healthcare landscape.

During this year’s AACR Annual Meeting we spoke to Dr. Delphine Lissa and Dr. Ana Robles from the National Cancer Institute to learn more about the team’s most recent study on the use of two specific biomarkers for risk stratification of stage I lung cancer patients.

We recently spoke to GenScript’s VP of Marketing, Eric Wang, to learn more about the company’s mission to “make people and nature healthier through biotechnology”. Eric discusses the key phases of antibody therapeutic discovery and development, GenScript’s role in advancing drug discovery research, and tells us about the company’s recently launched custom rabbit monoclonal antibody service.

To learn more about ContextVision, their move into the field of digital pathology, and how INIFY™ could help benefit pathologists and patients, we spoke to Lena Kajland Wilén, Director Business Unit Digital Pathology.

During this year’s AACR Annual Meeting we spoke to Julianna Supplee, Research Technician at the Robert and Renée Belfer Center for Applied Cancer Science at Dana-Farber Cancer Institute, to learn more about the team’s most recent study on the use of plasma HPV cell-free DNA as an early predictor of treatment response in patients with advanced oropharyngeal cancer.

During this year’s AACR conference we spoke to Kang Zhang, M.D., Ph.D. from the University of California, San Diego about the collaborative work he has been doing with the Laboratory for Advanced Medicine. He discusses their recent study findings on the use of a blood-based method to look at cell-free DNA as a marker for liver cancer diagnosis and prognosis.

Understanding the proteome is a fundamental challenge of biology. Here, Bruker Daltonics' Gary Kruppa and Scarlet Koch outline a new method, Parallel Accumulation Serial Fragmentation (PASEF) that offers faster, more sensitive and more robust proteome analysis, giving scientists the potential to discover low-level, biologically significant proteins and validate them in research.

Emulate, Inc. and AstraZeneca recently announced they have formed a collaborative partnership which will see Emulate's Organs-on-Chips technology embedded in AstraZeneca's Innovative Medicines and Early Development Biotech Unit.

To learn more about the impact AI has already had on diagnostics and health services, as well as some of its future capabilities, we spoke to Chris Scarisbrick.